Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | VCP | P55072 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399679 | 0.80 | AR (0.51) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL27551768 | 0.80 | KDM4E (0.57) | KMT2AMEN1KDM4ETSHRL3MBTL1 | |
| SCHEMBL19679620 | 0.78 | KMT2A (0.56) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL10922272 | 0.77 | GSTO1 (0.45) | KMT2AMEN1MAPTKDM4EPOLB | |
| SCHEMBL1915608 | 0.76 | AR (0.56) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL1916379 | 0.76 | NPC1 (0.58) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL1914839 | 0.76 | HSD17B10 (0.60) | KMT2AALDH1A1MEN1MAPTTDP1 | |
| SCHEMBL17150985 | 0.76 | MAOB (0.63) | KMT2AALDH1A1MEN1MAPTKDM4E | |
| SCHEMBL21225204 | 0.76 | RORC (0.47) | KMT2AALDH1A1MEN1MAPTTSHR | |
| SCHEMBL14048213 | 0.75 | MAPT (0.61) | KMT2AALDH1A1MEN1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| WO-2011076734-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076732-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING GASTROINTESTINAL DISORDERS | EUROSCREEN S.A. (BE) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | KMT2A 3648/4885ALDH1A1 623/4885MEN1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.